Fycompa generic availability?

What is the current status of Fycompa generic availability?

As of now [1], Fycompa, also known as perampanel, is a medication used for the treatment of epilepsy. It works by blocking the activity of AMPA receptors in the brain, which can help control seizures.

Has a generic version of Fycompa been approved?

According to the FDA's Orange Book, there are no approved generic versions of Fycompa available in the market [2]. However, it's essential to note that regulatory approval does not necessarily translate to timely market availability.

When can we expect a generic version of Fycompa?

The patent for Fycompa is set to expire in 2027, which means that generic manufacturers can start introducing their versions of the drug after that date. However, please note that the patent expiry timeline is subject to change, and it may be altered due to various factors, such as patent extensions or challenges.

Will other generic versions be available before the patent expiry?

It's a possibility that other generic versions of Fycompa could be approved and marketed before the patent expiry. Biosimilars, in particular, can be approved and marketed earlier if they meet the FDA's standards. However, the availability of these generic versions is still uncertain and subject to various regulatory and commercial considerations.

Can patients access Fycompa generics through programs like 340B or others?

While generic versions may not be available yet, patients may still be able to access Fycompa through various programs that offer discounted prices or assistance, such as the drug manufacturer's patient assistance program.

Sources:

[1] [www.drugpatentwatch.com] (accessed June 2024)
[2] [www.accessdata.fda.gov] (accessed June 2024)